Anticalins in Immuno-Oncology
Antibody-Anticalin multispecific fusion proteins can be used to pursue several innovative approaches in immuno-oncology, particularly when addressing the “immune synapse” between immune cells and cancer cells. One example is to drive an efficient activation of tumor-specific T cells within the vicinity of the tumors, the space called the tumor microenvironment, thereby avoiding some of the toxicity observed with peripheral T cell activation in healthy tissues. Pieris is committed to becoming a leader in developing tumor-localized T cell costimulatory agonists, led by its wholly owned lead candidate, PRS-343.
Additionally, Pieris is developing best-in-class multi-checkpoint antagonists built on key backbone components (e.g. PD-1), led by its PRS-332 program, which is partnered with Servier, with Pieris retaining full US rights. Finally, Pieris will strive to demonstrate intra-pipeline synergy between targeted costimulatory engagement and multi-checkpoint blockade within its own pipeline. A combination of 4-1BB (CD137) activation combined with PD-1 blockade, for instance, has demonstrated the potential to result in greater tumor growth inhibition than either monotherapy in preclinical studies.